Belkhair J, Sebbani M, Lachgar F, Baizri H, Amine M, Chellak S (2019). L'hyperhomocystéinémie chez une population diabétique type 2: prévalence et son association aux paramètres clinicobiologiques. Médecine des Maladies Métaboliques 13(6):556-560.
Crossref

Buysschaert M, Dramais AS, Wallemacq PE, Hermans D (2000). Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance. Diabetes care 23(12):1816-1822.
Crossref

Cisse F, Diallo F, Diatta A, Ndiaye A, Samba A, Thiam S, Sarr GN, Sall ND, Toure M (2015). Hyperhomocystéinémie et diabète de type 2. Revue CAMES Santé 3(1):9-12.

Diakoumopoulou E, Tentolouris N, Kirlaki E, Perrea D, Kitsou E, Psallas M, D. Doulgerakis D, Katsilambros N (2005). Plasma homocysteine levels in patients with type 2 diabetes in a Mediterranean population: relation with nutritional and other factors. Nutrition, Metabolism and Cardiovascular Diseases 15(2):109-117.
Crossref

Einarson TR, Acs A, Ludwig C, Panton UH (2018). Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientifc evidence from across the world in 2007-2017. Cardiovascular Diabetology 17(83):1-19.
Crossref

Goldstein M, Leibovitch I, Yeffimov I, Gavendo S, Sela BA, Löwenstein A (2004). Hyperhomocysteinemia in patients with diabetes mellitus with and without diabetic retinopathy. Eye 18(5):460-465.
Crossref

Guldener CV, Stehouwer CD (2002). Diabetes Mellitus and Hyperhomocysteinemia. Seminars in Vascular Medicine 2(1):87-96.
Crossref

Hoogeveen EK, Kostense PJ, Jakobs C, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CDA (2000). Hyperhomocysteinemia Increases Risk of Death, Especially in Type 2 Diabetes 5-Year Follow-Up of the Hoorn Study. Circulation 101(13):1506-1511.
Crossref

Jaegera C, Fraoucenea N, Voronskaa E, Cherinb P (2010). Rôle de l'homocystéine en pathologie. Médecine et Longévité 2(2):73-86.
Crossref

Kim J, Ahn CW, Sungsoon C, Lee HS, Suk PJ (2019). Association between metformin dose and vitamin B12 deficiency in patients with type 2 diabetes. Medicine 98(46):1-8.
Crossref

Mao C, Xiang W, Huang S, Zhang A (2014). Association between homocysteine status and the risk of nephropathy in type 2 diabetes mellitus. Clinica Chimica Acta 431(2014):206-210.
Crossref

Masaki T, Anan F, Anai M, Higuchi K, Tsubone T, Gotoh K, Chiba S, Katsuragi I, Tanaka K, Kakuma T, Yoshimatsu H (2007). Hyperhomocysteinemia is associated with visceral adiposity in Japanese patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice 77(2007):168-173.
Crossref

Moraba M, Sengwayo D, Motaung S (2013). Association of homocysteinaemia with hyperglycaemia, dyslipidaemia, hypertension and obesity. Cardiovascular Journal of Africa 24(7):265-269.
Crossref

Muzurovi? E, Kraljevi? I, Solak M, Dragni? S, Mikhailidis DP (2021). Homocysteine and diabetes: Role in macrovascular and microvascular complications. Journal of Diabetes and Its Complications 35(2021):1-16.
Crossref

Reis RP (2022). Homocysteinemia and vascular disease: Where we stand in 2022. Revista Portuguesa de Cardiologia 41(2022):821-822.
Crossref

Rigaud D (1999). Hyperhomocystéinémie et maladies cardiovasculaires dues à l'athérosclérose. La Lettre du Cardiologue 309:26-30.

Sabanayagam C, Shankar A (2011). Association between plasma homocysteine and microalbuminuria in persons without hypertension, diabetes mellitus, and cardiovascular disease. Clinical and Experimental Nephrology 15(1):92-99.
Crossref

Sato Y, Ouchi K, Funase Y, Yamauchi K, Aizawa T (2013). Relationship between metformin use, vitamin B12 deficiency, hyperhomocysteinemia and vascular complications in patients with type 2 diabetes. Endocrine Journal 60(12):1275-1280.
Crossref

Schalinske KL (2003). Interrelationship between Diabetes and Homocysteine Metabolism: Hormonal Regulation of Cystathionine β-Synthase. Nutrition Reviews 61(4):136-138.
Crossref

Sène D, Cacoub P (2013). Hyperhomocystéinémie: un vrai facteur de risque cardiovasculaire? EMC Cardiologie 8(1):1-7.
Crossref

Trabetti E (2008). Homocystein, MTHFR gene polymorphisms, and cardio-cerebrovascular risk. Journal of Applied Genetics 49(3):267-282.
Crossref

Wijekoon EP, Brosnan ME, Brosnan JT (2007). Homocysteine metabolism in diabetes. Biochemical Society Transactions 35(5):1175-1179.
Crossref

Xu JR, Zhang XY, Zhao L, Han QH (2022). Correlation between hypertension and high homocysteine levels caused by the MTHFR C677T gene polymorphisms. Asian Journal of Surgery. 45(4):1039-1040.
Crossref

Zendjabil M, Abbou O, Chellouai Z (2017). Association entre syndrome métabolique et hyperhomocystéinémie dans une population algérienne. Annales Pharmaceutiques Françaises 75(1):54-58.
Crossref

Zhang Y, Wang Q, Li Q, Lu P (2015). Association between Hyperhomocysteinemia and Thyroid Hormones in Euthyroid Diabetic Subjects. BioMed Research International 2015(196379):1-5.
Crossref